Atacicept for IgAN Will Be Focus of Two Presentations at ERA Congress

Vera Therapeutics announced that the ORIGIN phase 2b clinical trial of its drug atacicept for the treatment of IgA nephropathy (IgAN) will be the subject of two presentations at the 61st European Renal Association Congress (ERA24). ERA24 will take place May 23-26 in Stockholm, Sweden, and virtually.

Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor that binds to the cytokines B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL. These cytokines promote B-cell survival and autoantibody production associated with certain autoimmune diseases, including IgAN and lupus nephritis. Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful.

The oral presentations, both taking place on May 25, are “Glomerular Disease Center at Stanford University Medical Center Phase 2b ORIGIN Study Open Label Extension with Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria: Week 72 Interim Analysis,” presented by Richard Lafayette, MD, FACP, a professor of medicine, nephrology, and director of the Glomerular Disease Center at Stanford University Medical Center, and “Impact of Atacicept on Hematuria in IgA Nephropathy: Post-Hoc Analysis of the Phase 2b ORIGIN Study,” presented by Jürgen Floege, MD, senior professor, Division of Nephrology and Rheumatology, at the University of Aachen in Germany.